FreePeptideCalc

Survodutide Dosage Chart and Vial Calculator

Investigational glucagon and GLP-1 receptor dual agonist from Boehringer Ingelheim, licensed from Zealand Pharma, with published phase 3 obesity results. Not approved anywhere.

Written by , who builds and maintains this site and is not a clinician. Every figure links to its primary source.

Not approved

Investigational — not approved in any country

Survodutide has no approval from any regulator. Its first phase 3 obesity trial, SYNCHRONIZE-1, was published in the New England Journal of Medicine in 2026, and the FDA has granted it Breakthrough Therapy and Fast Track designations. Those designations speed up a review. They are not approvals, and we found no public record of a marketing application. The FDA lists survodutide among the drugs it has warned companies for selling illegally under “for research purposes” labels, and in August 2026 it named survodutide in a warning letter to a peptide seller.

No approved human dose exists for this compound in any country. The figures below are the doses used in named published studies, reproduced for reference only. Doses given to rats or mice do not convert to a human dose. The FDA has stated that labelling a product “research use only” or “not for human consumption” does not change its legal status when the seller's own marketing shows it is intended for people.

Anti-doping: Prohibited at all times. Falls under WADA class S0 (non-approved substances) by definition, because no regulator has approved it for human therapeutic use.

Calculator inputs

Set up your vial

Enter the label, dilution and dose. The result updates as you type.

Syringe volume
Syringe volume
Survodutide in the vial
Survodutide in the vial
The 1 mg default is an arithmetic example for the calculator, not a studied or recommended dose
Bacteriostatic water to add
Bacteriostatic water to add
Dose per injection
Dose per injection
No approved human dose exists for this compound. The dose shown is only a calculator input, not a recommendation or starting point.
More optionsReverse calculation, schedule and cost

Enter the bacteriostatic water you added and get the volume to draw.

Draw to
20units(0.2 mL)
20 units01020304050Drag the plunger, or focus it and use the arrow keys
Draw to 20 units on a 50-unit U-100 syringe.
Concentration
5 mg/mL
Water added
2 mL
Doses in vial
10
How the concentration is calculated

This divides the peptide by the water you add. The powder occupies a little volume of its own, which is negligible on a typical vial but not on one with a heavy bulking agent. When a product label states a concentration, use the label’s number.

Key facts

Molecular weight
4,232 DaPubChem formula C192H289N47O61 (CID 171378821). An acylated peptide; a retail vial's salt form is not accounted for.
Half-life
Not published. No accessible human pharmacokinetic study reports one, so any specific figure quoted elsewhere has no primary source behind it.
Also sold as
BI 456906, glucagon/GLP-1 dual agonist

Doses used in published studies

These are reproduced for reference. They are not recommendations, and an animal dose in mg/kg does not convert to a human dose.

humansubcutaneous, once weekly for 46 weeks

Maintenance doses of 0.6, 2.4, 3.6 or 4.8 mg, reached over a 20-week dose-escalation phase (fixed steps in weeks 1–10, then escalation every two weeks with some flexibility for tolerability), followed by 26 weeks at a fixed maintenance dose.

le Roux et al., phase 2 dose-finding trial NCT04667377, published in The Lancet Diabetes & Endocrinology in 2024; 387 adults with a BMI of 27 or more without diabetes. Mean weight change at 46 weeks by assigned dose was −6.2% at 0.6 mg, −12.5% at 2.4 mg, −13.2% at 3.6 mg and −14.9% at 4.8 mg, against −2.8% on placebo. Among participants who actually received 4.8 mg in maintenance, the figure was −18.7% against −2.3%.

humansubcutaneous, once weekly for 48 weeks

Maintenance doses of 2.4, 4.8 or 6.0 mg. Per the trial protocol, every group started at 0.3 mg and escalated every two weeks, in 0.3 mg steps at first and 0.6 mg steps at higher doses, over a rapid-escalation phase of up to 24 weeks, followed by 24 weeks of maintenance.

Sanyal et al., phase 2 MASH trial NCT04771273, published in the New England Journal of Medicine in 2024; 293 adults with biopsy-confirmed MASH and fibrosis stage F1–F3. MASH improved without worsening of fibrosis in 47%, 62% and 43% of the 2.4, 4.8 and 6.0 mg groups, against 14% on placebo.

humansubcutaneous, once weekly for 76 weeks

Up-titrated to 3.6 mg or 6.0 mg. The protocol's escalation scheme was longer than in phase 2 and allowed investigators to delay a step or drop one dose level for 2 to 4 weeks if gastrointestinal symptoms occurred.

SYNCHRONIZE-1, NCT06066515, published in the New England Journal of Medicine in 2026; 725 adults with obesity, or overweight with a complication, without diabetes. Under the treatment-regimen estimand, weight change at 76 weeks was −12.2% at 3.6 mg and −13.0% at 6.0 mg, against −5.4% on placebo. Assuming full adherence, the sponsor reported up to −16.6% against −3.2%.

humansubcutaneous, once weekly for 48 weeks

Survodutide 6.0 mg or placebo, randomised 2:1.

SYNCHRONIZE-MASLD, published in Nature Medicine in 2026; 216 adults with obesity and at-risk MASLD in the United States and Spain. A reduction of at least 30% in liver fat occurred in 68.5% on survodutide against 28.6% on placebo, with weight change of −8.7% against −1.4% under the treatment-regimen estimand.

How good is the evidence?

Strong for an unapproved drug: a published phase 2 obesity dose-finding trial, a phase 2 MASH trial with liver biopsies, and two published phase 3 trials (SYNCHRONIZE-1 in NEJM and SYNCHRONIZE-MASLD in Nature Medicine). Gastrointestinal effects were common: in SYNCHRONIZE-1 they affected 80.9% and 89.7% of the two survodutide groups against 47.9% on placebo. Results for people with type 2 diabetes (SYNCHRONIZE-2) and cardiovascular outcomes are not yet published. None of it concerns retail vials, whose identity and purity are unverified.

Survodutide dosage chart: what the trials actually did

Each survodutide trial reached its dose slowly. In the phase 2 obesity trial, 387 participants were assigned maintenance doses of 0.6, 2.4, 3.6 or 4.8 mg once weekly. They took 20 weeks to reach them and then stayed there for 26. In the phase 2 MASH trial, the protocol started every group at 0.3 mg and raised the dose every two weeks, first in 0.3 mg steps and later in 0.6 mg steps, until each group reached 2.4, 4.8 or 6.0 mg. Phase 3 settled on two doses, 3.6 mg and 6.0 mg, with an escalation the investigators describe as longer than the phase 2 one.

So the “survodutide peptide dosage” figures quoted online are the endpoints of these protocols, and the 0.3 mg “starting dose” is the first step of one of them. Participants were screened for eligibility and monitored throughout, and investigators could slow or reverse a step when gastrointestinal symptoms appeared. That is a record of what was studied, not a schedule. This site publishes no survodutide dosing schedule because no regulator has approved one.

Reading the phase 3 numbers

Two different figures for SYNCHRONIZE-1 are in circulation, and both are correct. The sponsor's April 2026 topline announcement reported weight loss of up to 16.6% at 76 weeks, against 3.2% on placebo. That figure uses the efficacy estimand, which assumes everyone kept taking the drug. The NEJM paper's primary analysis uses the treatment-regimen estimand, which counts people who stopped early or needed a longer escalation: −12.2% at 3.6 mg and −13.0% at 6.0 mg, against −5.4% on placebo.

The 6.0 mg dose added little over 3.6 mg on average and brought more gastrointestinal effects: 89.7% against 80.9%, compared with 47.9% on placebo. Results for SYNCHRONIZE-2, the trial in people with type 2 diabetes, had not been published at the time of writing.

Why there is no lawful compounded survodutide

Section 503A lets a compounder work from a bulk drug substance only if the substance has an applicable USP or NF monograph, is a component of an FDA-approved drug, or appears on the FDA's 503A bulks list. Survodutide meets none of these conditions. No approved drug contains it, and it does not appear among the substances nominated for the 503A list. Retail vials sold as survodutide are therefore unapproved new drugs.

The FDA has acted on this. In August 2026 it sent a warning letter to NuScience Peptides, which was selling survodutide, mazdutide and retatrutide as research peptides together with bacteriostatic water for reconstituting them. The agency's GLP-1 page lists survodutide among the drugs it has warned companies for selling with false “for research purposes” or “not for human consumption” labels, in some cases with dosing instructions.

Common questions

Sources

Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.

  1. Published studyThe Lancet Diabetes & Endocrinology· 2024-03
    le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
  2. Published studyNew England Journal of Medicine· 2024-07-25
    Sanyal AJ et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
  3. ReferenceBoehringer Ingelheim / ClinicalTrials.gov· 2023-07-27
    NCT04771273 (1404-0043) — survodutide phase 2 MASH clinical trial protocol
  4. Published studyNew England Journal of Medicine· 2026-08-20
    le Roux CW et al. Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1)
  5. Published studyObesity· 2025-01
    Wharton S et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2)
  6. Published studyDiabetes, Obesity and Metabolism· 2026-01
    le Roux CW et al. Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1)
  7. ReferenceZealand Pharma A/S· 2026-04-28
    Zealand Pharma announces Boehringer Ingelheim's survodutide achieved significant weight loss of 16.6% in people with obesity or overweight in Phase 3 trial (SYNCHRONIZE-1 topline)
  8. Published studyNature Medicine· 2026-08
    Kaplan LM et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
  9. ReferenceClinicalTrials.gov
    NCT06066528 — SYNCHRONIZE-2 phase 3 trial of survodutide in obesity with type 2 diabetes
  10. RegulatorFDA· 2026-09-01
    FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
  11. RegulatorFDA· 2026-08-24
    Warning Letter — NuScience Peptides LLC (survodutide sold as a research peptide)
  12. RegulatorFDA
    Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
  13. RegulatorFDA· 2026-05-14
    Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
  14. RegulatorWorld Anti-Doping Agency· 2026
    WADA 2026 Prohibited List
  15. ReferenceNIH / National Center for Biotechnology Information
    PubChem compound records (molecular weights and formulae)
  16. ReferenceU.S. National Library of Medicine
    ClinicalTrials.gov trial registry